VIENNA, Va., Sept. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation conducted an interview with SmallCap Network that was published Friday morning, September 22, 2006. The interview with the CEO of CEL-SCI, Geert Kersten, is in a question and answer format that addresses the current operations and future prospects of the Company. Interested parties may go to http://smallcapnetwork.net/archive/listserv/20060922-1.html to read the interview.
The SmallCap Network is a leading financial publisher dedicated to providing investors with information on equities in the small cap sector. They publish a weekly financial newsletter via email. The newsletter focuses on stocks in the small cap sector that have the potential to appreciate significantly in the future. With over 900,000 members, the SmallCap Network is one of the fastest-growing financial newsletters on the Internet.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company’s lead product Multikine(R) is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI’s other products, which are currently in the pre-clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
CEL-SCI Corporation
CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460
Web site: http://www.cel-sci.com/
